Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Published 1 month ago Positive
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
Auto

Related Stocks

APGE.US Apogee Therapeu... SNW.BE Sanofi SNW.DU Sanofi SNW.HA Sanofi SNW.MU Sanofi
Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.

Continue Reading

View Comments

More News

SoftBank unloads entire stake in Nvidia for $5.8B

1 hour ago Positive

Elliott said to challenge Toyota Industries’ privatization price as it builds stake

1 hour ago Positive

AUD/NZD eases from 1.1590, after hitting fresh 12-year highs

1 hour ago Positive

Earnings Snapshot: Rocket Lab surpasses Q3 expectations, sees stronger Q4 ahead

1 hour ago Positive

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München reports Q3 results; reaffirms FY outlook

2 hours ago Positive